BabyLux & MetaOx

Novel NIRS-DCS system are finally being commercialized!

Politecnico di Milano, together with ICFO and some other significant partners in Europe, is working on a project called “BabyLux – An Optical Neuro-Monitor of Cerebral Oxygen Metabolism and Blood Flow for Neonatology”  The project, funded by the European Commission, aims to provide an innovative and reliable tool to monitor and assess brain blood flow and oxygenation in extremely preterm neonates.
The device can be brought to the bedside, measurements can be done in a few minutes and repeatedly, if the condition is critical. The project takes up complete R&D works and extends already tested prototypes to the level of demonstrator, bridging the gap between research products and commercialization. It uses photonic technologies, such as diffuse correlation spectroscopy (DCS) and time resolved near-infrared spectroscopy (TRS). This innovative combination provides an accurate state-of-the-art and robustness in TRS, and introduces, for the first time, DCS in a combined instrument. After an initial laboratory demonstration, a trial period in real-life settings will follow, conducted in parallel both at the Mangiagalli Hospital in Milan (Italy) and at the Rigshospitalet in Copenhagen (Denmark). Functioning and benefits will be evaluated by professional end-users during validation tests, carried out in conditions fitting in the clinical workflow, protocols and procedures.

ISS has introduced MetaOx, a combined FDNIRS-DCS instrument for monitoring the cerebral oxygen metabolism (CMRO2) in infants using non-invasive optical techniques.  
Developed in collaboration with Prof. Franceschini of the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital and Prof. Yodh of the University of Pennsylvania, the instrument combines two advanced optical technologies – frequency-domain near-infrared tissue oximeter (FDNIRS) and diffusion correlation spectroscopy (DCS) – to meet a range of research and clinical needs.
Rapid and accurate assessment of cerebral metabolism at bedside is critical to improving patient management in neonatology. Currently, though, there is no bedside tool that can accurately screen for brain injury, monitor injury evolution or assess response to therapy. MetaOx addresses this by offering a direct measure of cerebral oxygen utilization, which provides higher sensitivity in detecting brain injury and an ability to monitor both normal and abnormal brain development.
More information @